Endocrinology News and Research

Latest Endocrinology News and Research

Report on evidence-based disease prevention programs released by TFAH and NYAM

Trust for America's Health (TFAH) and The New York Academy of Medicine (NYAM) released a new report today featuring a range of evidence-based disease prevention programs that have shown results for improving health and reducing costs in communities.

22 Sep 2009

"Help is Here Express" bus tour in South Carolina to provide prescription medicines for free

The "Help is Here Express" bus tour will be stopping in South Carolina throughout the week of September 21 - 25 at various cities in order to help uninsured and financially struggling South Carolinians access information on programs that provide prescription medicines for free or nearly free. With the state's unemployment rate now hitting 11.8 percent, the Partnership for Prescription Assistance (PPA) bus tour is raising awareness of patient assistance programs among state residents who face layoffs and loss of health care benefits.

22 Sep 2009

Three-year clinical results of Medtronic's Resolute Zotarolimus-Eluting Coronary Stent released

New clinical data released today at a major meeting of interventional cardiologists show strong and sustained efficacy and safety of the Resolute® Zotarolimus-Eluting Coronary Stent from Medtronic, Inc. (NYSE: MDT) in long-term patient follow-up.

22 Sep 2009

Gerresheimer opens new R&D and production centers in USA and Europe

The Gerresheimer Group expands its activities in the pharmaceutical plastic business with two strategically significant investments in the USA and Europe.

22 Sep 2009

Drug-eluting stents effective for diabetic patients

Results of a multicenter study in Asia, demonstrating that drug-eluting stents are effective with a low rate of complications in diabetic patients, will be presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

22 Sep 2009

Diabetes more prevalent in African Americans due to living conditions

The higher incidence of diabetes among African Americans when compared to whites may have more to do with living conditions than genetics, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health. The study, available online in advance of publication in the October 2009 edition of the Journal of General Internal Medicine, found that when African Americans and whites live in similar environments and have similar incomes, their diabetes rates are similar, which contrasts with the fact that nationally diabetes is more prevalent among African Americans than whites.

22 Sep 2009

MRS could be effective for identifying diabetes

Researchers have long suspected that overweight people tend to have large fat deposits in their pancreases, but they've been unable to confirm or calculate how much fat resides there because of the organ's location.

22 Sep 2009

Mathematical model of an ischemic wound

Scientists expect a new mathematical model of chronic wound healing could replace intuition with clear guidance on how to test treatment strategies in tackling a major public-health problem.

22 Sep 2009

XIENCE V Everolimus Eluting Coronary Stent System exhibits its advantages over the TAXUS system

Long-term data presented today from the SPIRIT III pivotal U.S. clinical trial demonstrated that the observed clinical advantages of Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System continued to increase as compared to the TAXUS(R) Express2 Paclitaxel-Eluting Coronary Stent System (TAXUS).

21 Sep 2009

Some religious groups seek health care for illegal immigrants

NPR reports: "In the Hispanic community, there are issues in the debate over health care that spill over into the debate over immigration policy."

21 Sep 2009

NIDDK grants HealthPartners Research Foundation $7.3M to study childhood obesity

Three new HealthPartners Research Foundation studies will examine ways to prevent and treat childhood obesity and hypertension. One study will look at interventions to prevent obesity in children ages 5-9, another will focus on obesity prevention in children ages 2-5, while another will examine hypertension in children and adolescents, including the quality and cost of care.

21 Sep 2009

Many Australians at risk of having a heart attack are not receiving the best possible care: Study

The research suggests that GPs are still managing individual risk factors such as blood pressure and cholesterol in isolation of one another, and are not adopting recommendations to treat a patient's overall or absolute risk. Absolute risk management is based on the principle that the major risk factors for cardiovascular disease act together. By taking this approach treatment can be targeted to those most likely to benefit.

21 Sep 2009

Medicare round up: News coverage of cost issues and leadership gap

"The national average for Medicare spending on such patients was $46,412, including outpatient care," the Times reports. "But in Los Angeles County, the average cost was nearly double that, $84,179, according to a Los Angeles Times review of Dartmouth data. In seeking to explain why, some researchers have concluded that doctors in areas such as Los Angeles, with more hospitals and other resources, are more likely to have patients admitted, order tests and schedule visits, largely because they can."

21 Sep 2009

New study reveals that large abdominal fat cells contribute to type 2 diabetes in women

Middle-aged women with large abdominal fat cells have a higher risk of developing type 2 diabetes later in life compared to women with smaller fat cells. Waist circumference divided by body height can also be used to determine which women are at risk. This is shown in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

21 Sep 2009

MDC scientist receives 1 million euros for diabetic research

A European Research Council (ERC) Starting Grant worth more than a million euros over the next five years has been awarded to Dr. Francesca M. Spagnoli of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch, Germany.

21 Sep 2009

QualityMetric announces new tool to measure pain accurately

According to the National Centers for Health Statistics, 76.2 million Americans report problems with chronic pain; more than diabetes, heart disease, and cancer combined. The same report notes that the annual cost of chronic pain in the United States, including healthcare expenses, lost income, and productivity, is estimated to be $100 billion.

21 Sep 2009

Phytel releases new version of its web-based Proactive Patient Outreach Solution

Phytel, the leading provider of information technology that empowers physician-led health improvement, today announced that version 5 of its web-based Proactive Patient Outreach Solution has been released and fully deployed to all of its customers.

21 Sep 2009

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

21 Sep 2009

Optimized diabetes management with the CONTOUR(R) USB blood glucose meter

Bayer Diabetes Care today announced U.S. Food & Drug Administration clearance to market the CONTOUR(R) USB blood glucose meter. Bayer's CONTOUR USB meter is the first and only blood glucose monitor that plugs directly into a computer providing users with instant access to information that can help optimize diabetes management. The CONTOUR USB meter is integrated with Glucofacts(TM) DELUXE software for easy retrieval of data as well as longer-term tracking and analysis of blood glucose test results.

21 Sep 2009

Ipsen's Azzalure muscle relaxant receives Spanish AEMPS marketing approval

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Euronext: IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin type A manufactured by Ipsen), a local muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Spain from the Spanish Medicines and Healthcare products Agency (AEMPS) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.

21 Sep 2009